Biotech: Page 32
-
Permission granted by Ajax Therapeutics
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.
By Gwendolyn Wu • May 13, 2024 -
Getty Images
NewVale, an unorthodox investment firm, sets out to support biotech’s ‘infrastructure’
The firm, which closed a $167 million fund, aims to fill a “crucial gap” by growing the companies startups turn to for outsourced services, founder Todd Holmes told BioPharma Dive.
By Ben Fidler • May 13, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona.
By BioPharma Dive staff • May 10, 2024 -
Permission granted by Maze Therapeutics
Maze lands new partner for Pompe drug, after Sanofi pact came apart
An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.
By Ben Fidler • May 10, 2024 -
Courtesy of Novo Nordisk
Novo taps another Flagship startup in search for next obesity drugs
The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.
By Gwendolyn Wu • May 9, 2024 -
Seth Babin/BioPharma Dive
Verve moves forward with backup base editing therapy
Weeks after a safety setback derailed its lead candidate, the company has treated the first participant in a trial of its heart disease treatment Verve-102.
By Ned Pagliarulo • May 7, 2024 -
Getty Images
Zenas, with new funding, aims dual-targeting antibody at lupus and MS
The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies.
By Ben Fidler • May 7, 2024 -
Permission granted by Prologue Medicines
Prologue, Flagship’s newest startup, looks to mine viruses for new drugs
The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.
By Gwendolyn Wu • May 7, 2024 -
Permission granted by Bluebird bio
Bluebird, Vertex prep for first commercial use of sickle cell gene therapies
One patient has started the treatment process for Bluebird's Lyfgenia, while five others have done the same for Vertex's Casgevy.
By Ned Pagliarulo • Updated May 7, 2024 -
Permission granted by Qiagen
Sponsored by QiagenFree pathway analysis: How much do you really save?
Can free bioinformatics tools get the job done?
May 6, 2024 -
Permission granted by Nasdaq, Inc.
CG follows big IPO with new results for bladder cancer drug
Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.
By Gwendolyn Wu • May 3, 2024 -
Carsten Koall via Getty Images
Activist investor pushes case against Novavax leadership
Shah Capital, which owns a 7.5% stake in Novavax, called for shareholders to vote against re-electing three of the vaccine maker’s director nominees.
By Meagan Parrish • May 3, 2024 -
Maddie Meyer via Getty Images
Moderna ends gene editing alliance with Metagenomi
Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.
By Kristin Jensen • May 2, 2024 -
Retrieved from National Cancer Institute on September 27, 2019
BridgeBio spinout launches with $200M for KRAS cancer drugs
The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.
By Ned Pagliarulo • Updated May 2, 2024 -
Permission granted by Delphia Therapeutics
Delphia starts up with $67M to make a new type of cancer drug
The startup is developing medicines designed to overstress cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.”
By Gwendolyn Wu • May 2, 2024 -
Getty Images
Reunion raises over $100M to build a better psychedelic drug
The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.
By Jacob Bell • May 2, 2024 -
Permission granted by Enlaza Therapeutics
Enlaza gets JP Morgan, Regeneron backing for covalent biologics
The funds will help the cancer-focused startup Enlaza bring several candidates toward human testing in the next few years, its CEO said.
By Gwendolyn Wu • April 30, 2024 -
Permission granted by Bristol-Myers Squibb
Repertoire pivot pays dividends with Bristol Myers deal
The alliance validates the new direction pursued by Repertoire, a startup that cut staff and switched CEOs in 2022 after research on personalized cell therapies disappointed.
By Gwendolyn Wu • April 29, 2024 -
Getty Images
BioMarin drops drug programs in pipeline cull
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
By Kristin Jensen • April 25, 2024 -
Permission granted by Regeneron
Regeneron expands in gene editing with Mammoth deal
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
By Gwendolyn Wu • April 25, 2024 -
Permission granted by Biogen
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
By Jacob Bell • April 24, 2024 -
Maddie Meyer via Getty Images
Moderna turns to AI to change how its employees work
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
By Ned Pagliarulo • April 24, 2024 -
Courtesy of Eisai
Biogen to invest more in launch of Alzheimer’s drug Leqembi
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.
By Jacob Bell • April 24, 2024 -
William Walker/BioPharma Dive
Sponsored by Allucent[Podcast] Partner for Progress: Strategies for Biotech Success
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness.
Updated June 3, 2024 -
Courtesy of CureVac AG
CureVac to cut costs in restructuring
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.
By Kristin Jensen • April 24, 2024
Previous
